Tetra Radar · FDA Approvals · Decision date
RP1: FDA decision date
Theriva Biologics, Inc. (TOVX) · 10 April 2026
A BLA resubmission by Replimune, Inc. for their OV RP1 (vusolimogene oderparepvec) in combination with nivolumab for patients with advanced melanoma has been accepted by the FDA with a Prescription Drug User Fee Act (PDUFA) action date of April 10, 2026.
Source: 10-K of 12 March 2026
The date has passed; Tetra Radar has not recorded an approval.
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.